Virax Biolabs Group Ltd (NASDAQ:VRAX) shares, rose in value on Thursday, April 16, with the stock price down by -3.54% to the previous day’s close as strong demand from buyers drove the stock to $0.99.
Actively observing the price movement in the last trading, the stock closed the session at $1.03, falling within a range of $0.9633 and $1.05. The value of beta (5-year monthly) was 1.798. Referring to stock’s 52-week performance, its high was $9.00, and the low was $0.60. On the whole, VRAX has fluctuated by -19.23% over the past month.
With the market capitalization of Virax Biolabs Group Ltd currently standing at about $4.31 million, investors are eagerly awaiting this quarter’s results, scheduled for in May.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 25k, with a low estimate of 10k and a high estimate of 10k. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 10k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that VRAX’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of VRAX currently trading nearly -8.05% and -28.53% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 39.74, while the 7-day volatility ratio is showing 15.80% which for the 30-day chart, stands at 10.54%. Furthermore, Virax Biolabs Group Ltd (VRAX)’s beta value is 1.74, and its average true range (ATR) is 0.13.
A comparison of Virax Biolabs Group Ltd (VRAX) with its peers suggests the former has fared considerably weaker in the market. VRAX showed an intraday change of -3.54% in last session, and over the past year, it grew by 52.71%%.
Data on historical trading for Virax Biolabs Group Ltd (NASDAQ:VRAX) indicates that the trading volumes over the past 10 days have averaged 0.53 and over the past 3 months, they’ve averaged 256.76K. According to company’s latest data on outstanding shares, there are 4.34 million shares outstanding.
Nearly 6.63% of Virax Biolabs Group Ltd’s shares belong to company insiders and institutional investors own 6.70% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.14 million shares as on 2025-03-31, resulting in a short ratio of 1.06. According to the data, the short interest in Virax Biolabs Group Ltd (VRAX) stood at 343.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 0.2 million. The stock has fallen by -55.84% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the VRAX stock heading into the next quarter.
